Shu Ying Chen

US Patent:

8529882, Sep 10, 2013

Filed:

Jul 3, 2012

Appl. No.:

13/541436

Inventors:

Robert Edward Babine - Franklin MA, US
Shu Hui Chen - Carmel IN, US
Ivan Collado - Madrid, ES
Cristina Garcia-Paredes - Madrid, ES
John Irvin Glass - Indianapolis IN, US
Ling Jin - Carmel IN, US
Jason Eric Lamar - Indianapolis IN, US
Nancy June Snyder - Lizton IN, US
Xicheng David Sun - Superior CO, US
Deqi Guo - Carmel IN, US
Yvonne Yee Mai Yip - Indianapolis IN, US
Frantz Victor - Indianapolis IN, US
Mark Joseph Tebbe - Hamburg, DE
Robert B. Perni - Marlborough MA, US
Luc Farmer - Montreal, CA

Assignee:

Vertex Pharmaceuticals Incorporated - Cambridge MA

International Classification:

A61K 38/07
A61K 38/20
A61K 38/21
C07D 209/52
C12N 5/073
C12N 9/99
A61P 31/14
C07K 5/117

US Classification:

424 852, 424 854, 424 857, 435184, 435375, 517 43, 530330, 548515

Abstract:

The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel stereoselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.

US Patent:

20120064034, Mar 15, 2012

Filed:

Nov 10, 2011

Appl. No.:

13/293812

Inventors:

ROBERT EDWARD BABINE - FRANKLIN MA, US
SHU HUI CHEN - CARMEL IN, US
IVAN COLLADO - MADRID, ES
CRISTINA GARCIA-PAREDES - MADRID, ES
JOHN IRVIN GLASS - INDIANAPOLIS IN, US
DEQI GUO - CARMEL IN, US
LING JIN - CARMEL IN, US
JASON ERIC LAMAR - INDIANAPOLIS IN, US
NANCY JUNE SNYDER - LIZTON IN, US
XICHENG DAVID SUN - SUPERIOR CO, US
YVONNE YEE MAI YIP - INDIANAPOLIS IN, US
FRANTZ VICTOR - INDIANAPOLIS IN, US
MARK JOSEPH TEBBE - HAMBURG, DE
ROBERT B. PERNI - MARLBOROUGH MA, US
LUC FARMER - FOXBOROUGH MA, US

Assignee:

VERTEX PHARMACEUTICALS INCORPORATED - CAMBRIDGE MA

International Classification:

A61K 38/08
C07K 5/037
A61K 38/21
C12N 5/071
C07C 229/42
C07D 209/52
C12N 9/99
C07K 7/06
A61K 38/20

US Classification:

424 852, 530330, 514 37, 424 854, 424 857, 560 43, 548512, 548515, 435184, 435375

Abstract:

The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.